

Ulcerative Colitis

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

Trial Status
Completed

Trial Runs In
15 Countries

Trial Identifier
NCT02165215 2013-004280-31
GA29102

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely active UC who are naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02165215 2013-004280-31 GA29102
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years & ≤ 80 Years

Healthy Volunteers
No
